Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symptom burden and outcomes among patients with early-onset versus average-onset neuroendocrine neoplasms.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Effect of Treatment Delay on Outcomes With Adjuvant Chemotherapy Versus Chemoradiotherapy in R1-Resected Biliary Tract Cancers.

American journal of clinical oncology·2026
Same author

Tarlatamab in Previously Treated Small Cell Lung Cancer: A Real-World Experience in a Predominantly Hispanic Population with CNS Metastases.

Cancers·2026
Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Sclerosing Rhabdomyosarcoma Arising in Desmoid Fibromatosis 17 Years After Therapeutic Radiation.

JBJS case connector·2026
Same author

MRI-Based Delta Necrosis as a Prognostic Marker Following Neoadjuvant Chemotherapy in Soft Tissue Sarcoma.

Cancers·2026

Related Experiment Video

Updated: May 22, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.2K

Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?

Amrit Paudel1, Priya Chattopadhyay2, Brandon Rose2

  • 1Department of Medicine, Division of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.

Cancers
|March 13, 2025
PubMed
Summary

Soft tissue sarcomas (STSs) are rare, diverse tumors. Current treatments include surgery and chemotherapy, but advanced STSs have low survival rates, necessitating new therapies.

Keywords:
anthracyclineschemotherapyimmunotherapysoft tissue sarcomatyrosine kinase inhibitors

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.8K

Related Experiment Videos

Last Updated: May 22, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.8K

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • Soft tissue sarcomas (STSs) are rare cancers originating from mesodermal tissues.
  • Over 100 subtypes exist, each with unique clinical behavior and treatment responses.
  • Localized STS treatment involves surgery, radiation, and chemotherapy, but metastasis is common.

Purpose of the Study:

  • To review current systemic treatment strategies for soft tissue sarcomas (excluding GISTs).
  • To highlight recent advancements in STS therapy.
  • To explore future directions in managing advanced metastatic STS.

Main Methods:

  • Literature review of current systemic therapies for STS.
  • Analysis of pathological, immunohistochemical, and molecular features guiding treatment.
  • Examination of anthracycline-based chemotherapy, targeted therapy, and immunotherapy.

Main Results:

  • Anthracycline-based chemotherapy is the primary systemic treatment for advanced STS.
  • Survival rates for most advanced STS subtypes remain low despite current therapies.
  • Research is expanding treatment options beyond chemotherapy.

Conclusions:

  • Histology-specific approaches integrating molecular data are crucial for STS treatment.
  • Improving response rates and survival in advanced STS requires novel systemic therapies.
  • Targeted therapy and immunotherapy represent promising future directions for STS management.